Pfizer (NYSE:PFE) and its German partner BioNTech (BNTX) disclosed Phase 2/3 data on Saturday to indicate that the companies’ Omicron-adapted vaccine candidates generated a stronger immune response ...

Pfizer and BioNTech have paused a large U.S. clinical trial designed to test their updated COVID-19 vaccine in healthy adults aged 50 through 64, citing an inability to recruit enough participants.

Add Yahoo as a preferred source to see more of our stories on Google. Pfizer Inc. signage is seen on July 22, 2020 in New York City. Pfizer and partner BioNTech said they will halt a ...

Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) announced on August 27 that the U.S. FDA has approved the supplemental Biologics License Application for their 2026–2027 COVID-19 vaccine formula, ...

Pfizer (PFE) and BioNTech (BNTX) have halted recruitment for a large U.S.-based clinical trial designed to test their updated COVID-19 vaccine in healthy adults aged 50-64 years, citing challenges in ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Pfizer and its German partner BioNTech are ending a clinical trial they agreed to run in 2025 when receiving approval from U.S. authorities for their updated COVID-19 immunization. A BioNTech ...

LONDON, April 1 (Reuters) - Vaccine makers Pfizer and BioNTech halted a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to 64, saying enrollment in the trials had been too ...

Pfizer (PFE) and BioNTech (BNTX) have halted recruitment for a large U.S.-based clinical trial designed to test their updated COVID-19 vaccine in healthy adults aged 50-64 years, citing challenges in ...

Florida Attorney General James Uthmeier filed a lawsuit Thursday against Pfizer Inc., alleging unfair and deceptive marketing ...